Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the company's performance but did not provide detailed insights. The lack of guidance suggests uncertainty about future prospects.
Management did not provide specific revenue figures or guidance for the upcoming period.
The company acknowledged challenges in the current market environment.
The earnings report indicates that Kodiak Sciences is facing difficulties, as evidenced by the significant drop in stock price following the announcement. The stock fell by over 24%, reflecting investor concerns about the company's financial health and future performance. The absence of revenue figures and guidance adds to the uncertainty surrounding the company's outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ZTO EXPRESS CAYMAN I Class A ADR
Mar 16, 2020